Coya Plans Open-Label Extension of ALSTARS Phase 2/3 Trial
Coya plans to initiate an open-label extension to continue COYA 302 treatment and collect longer-term ALS data. The company also delayed its FTD trial to 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Coya Plans ALS Trial Extension, Pushes FTD Trial to 2027
Coya expects to begin an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS in November 2026. The company now expects its Phase 2 FTD trial to start in 2027; cash runway guidance remains into H2 2027.
Coya to Initiate Open — Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
For best results when printing this announcement, please click on link below: Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS OLE planned in response to requests from ALSTARS investigators and participants Eligible participants completing 48 weeks of treatment will have the opportuni
Coya Plans Open-Label Extension of Phase 2/3 ALSTARS Trial
Coya Therapeutics plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS.